Funded Biotechnology Startups in Zürich
Disclosed round sizes in this Zürich biotechnology set are clustered in the single-digit millions, but one disclosed outlier stands out: Sequana Medical’s…
Disclosed round sizes in this Zürich biotechnology set are clustered in the single-digit millions, but one disclosed outlier stands out: Sequana Medical’s $2M (2025-12-05) is the most recent entry, while the largest disclosed amount overall is Molecular Partners’ $20M (2024-10-25), which is materially above most other disclosed rounds (several are $24M or higher only two steps away, and multiple entries sit at $2M). The earliest disclosed round among these 18 rows dates to 2021-09-02 (IDUN Technologies, Seed, $2M), while the most recent is 2025-12-05, spanning a multi-year window.
Stage and classification signals are mixed: “Series Unknown” appears frequently (five of the 18 rows), and there is one fully “undisclosed” amount (Arktis Radiation Detectors on 2025-04-23). City naming also clusters tightly around Zürich—16 of 18 rows list “Zürich, Zurich, Switzerland,” with the remaining two still in Zürich (TOLREMO therapeutics) and Zurich (spelling variant: TOLREMO therapeutics). Temporal concentration shows a heavy run in 2024, including multiple $2M–$20M disclosed rounds between 2024-02 through 2024-11.
Most recent rounds
18 shownRelated listings
Frequently asked
What’s the largest disclosed round here, and how far above the typical disclosed amounts is it?
The largest disclosed amount is Molecular Partners’ $20M on 2024-10-25. Many other disclosed rounds in the list are $2M (e.g., Sequana Medical $2M on 2025-12-05, CellX Biosolutions $2M on 2025-02-25, and IDUN Technologies $2M on 2021-09-02), with several others clustered below $10M (e.g., Microcaps $10M on 2024-06-05 and Hemotune $16M on 2024-03-25).
How concentrated are these biotech financings around the 2024 time window?
A large share of rounds fall in 2024, including Sequana Medical’s later-late entries in 2024 (e.g., Molecular Partners $20M on 2024-10-25, Microcaps $10M on 2024-06-05, and Hemotune $16M on 2024-03-25). By contrast, the earliest dated entry is 2021-09-02 (IDUN Technologies), indicating fewer entries at the beginning of the span.
Are there notable classification outliers from a stage-disclosure perspective?
Disclosure is uneven: “Series Unknown” appears in five of 18 rows (e.g., Trilliome 2025-10-16 at $60K; Relief Therapeutics 2023-06-16 at $6M; BC Platforms 2022-11-08 at $20M). Separately, Arktis Radiation Detectors (2025-04-23) is the only row marked “undisclosed,” which prevents size-based comparisons for that entry.
Which stage types dominate the disclosed mix versus specific large rounds?
Seed and Series A show recurring presence among explicitly sized rounds (e.g., SEITO Biologics Seed $3M on 2025-06-11; Oncobit Seed $2M on 2024-11-11; Microcaps Series A $10M on 2024-06-05). Meanwhile, the top-end disclosed size sits with Molecular Partners at $20M (2024-10-25), rather than being concentrated in the smallest stages only.
Is Zürich the only geography here, or do any entries diverge in naming or location within the city?
The geography is tightly clustered: 16 of 18 rows explicitly list “Zürich, Zurich, Switzerland,” with two additional variants still tied to Zürich (TOLREMO therapeutics lists “Zurich, Switzerland” on 2023-09-20). No other city appears outside this Zurich naming pattern.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.